J
Jacob Schachter
Researcher at Sheba Medical Center
Publications - 182
Citations - 18850
Jacob Schachter is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Melanoma & Pembrolizumab. The author has an hindex of 47, co-authored 163 publications receiving 15057 citations. Previous affiliations of Jacob Schachter include Tel Aviv University.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert,Caroline Robert,Caroline Robert,Jacob Schachter,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Omid Hamid,Christine Mateus,Christine Mateus,Ronnie Shapira-Frommer,Ronnie Shapira-Frommer,Michele Kosh,Honghong Zhou,Nageatte Ibrahim,Scot Ebbinghaus,Antoni Ribas +26 more
TL;DR: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Journal ArticleDOI
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroiakovski,Michael Lichinitser,Reinhard Dummer,Florent Grange,Laurent Mortier,Vanna Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Paul Lorigan,Pascal Wolter,Georgina V. Long,Keith T. Flaherty,Paul Nathan,Antoni Ribas,Antoni Ribas,Anne-Marie Martin,Peng Sun,Wendy A. Crist,Jeff Legos,Stephen D. Rubin,Shonda M Little,Dirk Schadendorf +27 more
TL;DR: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Journal ArticleDOI
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas,Igor Puzanov,Reinhard Dummer,Dirk Schadendorf,Omid Hamid,Caroline Robert,F. Stephen Hodi,Jacob Schachter,Anna C. Pavlick,Karl D. Lewis,Lee D. Cranmer,Christian U. Blank,Steven J. O'Day,Paolo A. Ascierto,April K.S. Salama,Kim Margolin,Carmen Loquai,Thomas Eigentler,Tara C. Gangadhar,Matteo S. Carlino,Sanjiv S. Agarwala,Stergios J. Moschos,Jeffrey A. Sosman,Simone M. Goldinger,Ronnie Shapira-Frommer,Rene Gonzalez,John M. Kirkwood,Jedd D. Wolchok,Alexander M.M. Eggermont,Xiaoyun Nicole Li,Wei Zhou,Adriane M Zernhelt,Joy Lis,Scot Ebbinghaus,S. Peter Kang,Adil Daud +35 more
TL;DR: In this article, the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma were compared.
Journal ArticleDOI
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V. Long,A. Hauschild,M. Santinami,Victoria Atkinson,M. Mandal,Vanna Chiarion-Sileni,James Larkin,Marta Nyakas,Caroline Dutriaux,Andrew Haydon,Caroline Robert,Laurent Mortier,Jacob Schachter,Dirk Schadendorf,Thierry Lesimple,Ruth Plummer,R. Ji,Ping Zhang,Bijoyesh Mookerjee,Jeffrey J. Legos,Richard F. Kefford,Reinhard Dummer,John M. Kirkwood +22 more
TL;DR: Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvantUse of placebo and was not associated with new toxic effects.
Journal ArticleDOI
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter,Antoni Ribas,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Honghong Zhou,Scot Ebbinghaus,Nageatte Ibrahim,Caroline Robert +19 more
TL;DR: The final protocol-specified survival analysis as mentioned in this paper showed that pembrolizumab continued to provide superior overall survival versus ipilimumab, with no difference between the two dosing schedules.